By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news originating from Rome, Italy, by NewsRx correspondents, research stated, "The antitumor activity of chimeric antigen receptor (CAR)-redirected CTLs should be enhanced if it were possible to increase their proliferation and function after adoptive transfer without concomitantly increasing the proliferation and function of regulatory T cells (Treg). Here, we explored whether the lack of IL-7R alpha in Treg can be exploited by the targeted manipulation of the interleukin-7 (IL-7) cytokine-cytokine receptor axis in CAR-engrafted Epstein-Barr Virus-specific CTLs (EBV-CTLs) to selectively augment their growth and antitumor activity even in the presence of Treg."
Our news journalists obtained a quote from the research from Institute for Cancer Research and Treatment (IRCCS), "We generated a bicistronic retroviral vector encoding a GD2-specific CAR and the IL-7R alpha subunit, expressed the genes in EBV-CTLs, and assessed their capacity to control tumor growth in the presence of Treg in vitro and in vivo when exposed to either interleukin-2 (IL-2) or IL-7 in a neuroblastoma xenograft. We found that IL-7, in sharp contrast with IL-2, supports the proliferation and antitumor activity of IL-7R alpha. CAR-GD2(+) EBV-CTLs both in vitro and in vivo even in the presence of fully functional Treg. IL-7 selectively favors the survival, proliferation, and effector function of IL-7R alpha-transgenic/CAR-redirected EBV-CTLs in the presence of Treg both in vitro and in vivo."
According to the news editors, the research concluded: "Thus, IL-7 can have a significant impact in sustaining expansion and persistence of adoptively CAR-redirected CTLs."
For more information on this research see: Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition. Clinical Cancer Research, 2014;20(1):131-139. Clinical Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Clinical Cancer Research - clincancerres.aacrjournals.org/)
The news correspondents report that additional information may be obtained from S.K. Perna, Osped Pediat Bambino Gesu, IRCCS, Dipartimento Ematol & Oncol Pediat, Rome, Italy. Additional authors for this research include D. Pagliara, A. Mahendravada, H. Liu, M.K. Brenner, B. Savoldo and G. Dotti (see also Biotechnology).
Keywords for this news article include: Rome, Biotechnology, Italy, Europe, Therapy, Genetics, Immunology, Blood Cells, Interleukins, Epstein-Barr Virus, Mononuclear Leukocytes, Cytotoxic T-Lymphocytes, Hemic and Immune Systems, CD8-Positive T-Lymphocytes, Cytokine-Induced Killer Cells
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC